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INTRODUCTION 
Molecular genetics started to progress after the discovery of the double helix 
structure of DNA in 1953. After the development of Sanger sequencing in the 
1970s to identify the sequence of bases in the DNA, the need for new techno-
logies has grown tremendously. As a sign of a great effort, the first human ge-
nome was sequenced in 2000. Since then, the development of the second 
generation sequencing or so-called ‘next-generation sequencing’ (NGS) has 
rapidly evolved. Advances in NGS technology have led us to the situation 
where we can, in a cost-effective way, identify the full spectrum of genetic 
variation across the genome. 
In connection with the development of ultra-high-throughput sequencing, 
there is a demand for better computational methods and resources. It all stems 
from the bioinformatics challenge that millions to billions of sequenced short 
DNA reads, 35–300 base pairs long, have to be put back together. 
Many nations have launched a large-scale genomic analysis of their popula-
tion, including Estonia. As a pioneer, Estonian Biobank has collected, analysed, 
and integrated genomic data for a long time. Almost 10 years ago, we started to 
generate and process NGS data and I have played a role in this process from the 
first day. There are many useful applications for the NGS data and I present 
some of them in my thesis. In the first part, I give an overview of exome se-
quencing and its use in medical genetics. In particular, I give an overview on 
how to detect rare and de novo mutations underlying Mendelian diseases. 
Whole genome sequencing is introduced in the next part, where I show its 
importance in covering the full spectrum of genome at a scale not previously 
attainable. Also, to perform large-scale association analysis more efficiently, I 
introduce an imputation reference panel specific to Estonians and show its 
advantages in imputing genetic variants, especially rare ones. 
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1. REVIEW OF THE LITERATURE 
1.1. Introduction to genetics 
Genetics is a branch of biology that studies the heritability and variation in 
organisms. DNA (deoxyribonucleic acid) is the hereditary material present in 
the nucleus of almost every cell of an organism. The information in DNA is 
stored as a code based on only four chemical bases (nucleotides): adenine (A), 
cytosine (C), guanine (G), and thymine (T). The full human DNA sequence 
contains more than 3 billion nucleotides present as base pairs (bps), and more 
than 99% of those bases are the same in all individuals. The sequence of these 
bases determines phenotypic characteristics (e.g. gender and blood type) and 
retains the information necessary for building and maintaining an organism. 
Human DNA is bundled into 46 chromosomes – 22 pairs of autosomes and one 
pair of allosomes (sex chromosomes). The autosome pairs are numbered (1–22), 
while the allosome pair usually consists of two X chromosomes in women or 
one X and one Y chromosome in men. Having two copies of each chromosome 
makes humans diploid organisms. 
Only a small fraction of the human DNA (~1–2%) contains protein-coding 
regions. These regions are called genes, where coding parts (exons) are inter-
rupted by noncoding parts (introns). It is estimated that there are ~20,000 
human protein-coding genes (Ezkurdia et al. 2014). During transcription, the 
entire gene is copied into a pre-mRNA (messenger ribonucleic acid), and during 
the process of RNA splicing, introns are removed and the resulting mRNA is 
translated into amino acids to form proteins. Except for the genes, the exact 
functional role of the large majority of the DNA remains unclear (Rands et al. 
2014) (however, it has been found that great deal of genetic variation is hidden 
in the form that do not produce obvious phenotypic differences). 
Each gene resides at a specific locus (location on a chromosome) in two 
copies, one copy of the gene inherited from each parent. At each genomic posi-
tion, one copy of the gene is named as allele and two copies together are refer-
red as genotype. A given gene may have multiple different alleles, though only 
two alleles are present at the locus of any individual. The alleles may differ 
from each other (heterozygous genotype) or be the same (homozygous geno-
type). The relative frequency of an allele at a locus in a particular population is 
the allele frequency. Allele frequencies may vary between human populations 
(e.g. between geographical or ethnic groups).  
There can be differences in both the composition and the structure of the 
DNA between individuals. Single nucleotide variants (SNVs) occur when a 
single base (A, C, G, or T) is altered in the DNA sequence and are the most 
common type of genetic variation. A subclass of SNVs are called as single-
nucleotide polymorphisms (SNPs), corresponding to the SNVs where at least a 
certain proportion (e.g. > 1%) of individuals carry a different nucleotide than 
the majority of the population at a specific locus. SNVs may fall within coding 
sequences of genes, non-coding regions of genes, or in the regions between 
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genes (intergenic regions). SNVs within the coding sequence may change the 
amino acid sequence of the produced protein, but do not do it necessarily, due 
to the degeneracy of the genetic code. SNVs in the coding region that do not 
affect the protein sequence are called synonymous, in contrast to nonsynony-
mous variants that change the amino acid sequence of a protein. SNVs that are 
not in protein-coding regions may still affect gene splicing, transcription factor 
binding, mRNA degradation, or the sequence of noncoding RNA. 
Small insertions or deletions (indels) occur when a stretch of DNA ranging 
from a single nucleotide to 1 kilobase (kb) in the genome is either present or 
absent. Small indels are the second most frequent type of genetic variation in 
human genomes. In terms of base pair variation, indels cause similar level of 
variation as SNVs. Structural variations (SVs) are generally defined as a regions 
of DNA approximately 1 kb and larger in size (Freeman et al. 2006) and can 
include inversions, balanced translocations or genomic imbalances (indels), 
commonly referred to as copy number variations (CNVs), because they effecti-
vely change the DNA copy number (the number of copies of a particular gene 
in the genotype of an individual). Despite the fact that small indels are highly 
abundant, they have received far less attention compared to SNVs and SVs, be-
cause they are more challenging to detect and validate (Mullaney et al. 2010). 
Meiosis is a specialized type of cell division that reduces the chromosome 
number by half. During meiosis, one maternal and one paternal chromosome 
form a pair of homologous chromosomes and exchange parts of their DNA 
(genetic recombination), resulting in the recombination of the two original 
chromosomes. Due to the genetic recombination, the offspring have a different 
set of alleles and genes compared to their parents. A particular set of alleles at 
linked loci that are present on one of the two homologous chromosomes are 
called haplotype blocks. The non-random association between loci within a 
haplotype block is called linkage disequilibrium (LD).  
For a set of 𝑁  heterozygous SNVs, there are 2ே  possible haplotypes that 
could underlie the genotypes (Figure 1). However, in the presence of LD within 
this set, the number of actual haplotypes that are present in the population can 
be considerably smaller. Knowledge of the LD structure within the population 
makes it possible to identify a set of tagging SNPs (tag SNPs) – once the geno-
types of these SNPs are known, the entire haplotype block is uniquely deter-
mined (or at least known with a sufficiently high probability). 
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Figure 1. SNPs, haplotypes and tag SNPs. SNPs and haplotypes from the same geno-
mic regions in four individuals are illustrated. (A) Three SNPs with two possible alleles 
are highlighted in different colours, rest of the loci are identical (black). (B) Haplotypes 
are combinations of alleles that are inherited together and are located at nearby SNPs on 
the same chromosome. In total, 23 SNPs are presented, and three are from the panel 
(A). (C) Three tag SNPs out of the 23 SNPs are sufficient to identify these four haplo-
types uniquely. 
 
 
1.2. Next-generation sequencing 
Since the discovery of the double helix structure of DNA (Watson & Crick 
1953) and the development of Sanger sequencing (Sanger & Coulson 1975) to 
detect the sequence of DNA bases, the field of DNA sequencing has rapidly 
progressed. Sanger sequencing method provides ultimate resolution for genome 
analysis, but is limited by the low number (96) of parallel reactions, which 
makes it time consuming and expensive. Despite that, it was the most widely 
used sequencing method for approximately 40 years and remains in wide use 
for smaller-scale projects. 
Over the last two decades, technologies across multiple fields were brought 
together in the development of so-called ‘next-generation’ or ‘massively paral-
lel shotgun’ sequencing instrument for large-scale, routine sequencing. This 
phenomenon was especially true at the beginning of the current century, largely 
because of the efforts of Human Genome Project to sequence the human ge-
nome (Lander et al. 2001; Venter et al. 2001; Human Genome Sequencing Con-
sortium 2004). Since then, the number of companies involved in NGS and 
developed technologies has increased rapidly, along with the corresponding 
field of bioinformatics. Today, NGS is a commonly used term describing ultra-
high-throughput sequencing methods that allow the sequencing of millions to 
billions of DNA fragments in a single instrument run. The cost of DNA se-
quencing has fallen from a billion dollars (the first human genome) to a few 
thousands of dollars (nowadays) per human genome. In addition to rapid turna-
round and reasonable price compared to the previous methods, NGS allows 
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studying all kinds of genomic variation (e.g. SNVs, indels, SVs) in a single 
experiment. 
Although sequencing instruments differ in many aspects, they rely on a few 
conceptually similar core technologies (Metzker 2010). Several distinct NGS 
platforms are commercially available, the most well-known manufacturers cur-
rently are Illumina (Bentley et al. 2008), Pacific Biosciences (Eid et al. 2009), 
Ion Torrent (Rothberg et al. 2011), and Oxford Nanopore (Quick et al. 2014). 
Detailed overviews of existing sequencing platforms and their properties are 
given by Reuter et al. (2015), Levy and Myers (2016). 
Currently, Illumina’s platforms dominate the sequencer market share. The 
HiSeq 2500 System features two run modes: a high-throughput mode, which 
outputs up to one terabase (Tb) of data (up to four billion reads) in six days, and 
a quick but less cost-effective rapid mode, which produces a 30× coverage (the 
number of sequenced bases at given position) human genome in 27 hours. The 
HiSeq X Ten System is specialized for WGS. It consists of a set of 10 HiSeq X 
instruments, able to deliver 18,000 human genomes at 30× coverage per year. 
The performance of different NGS instruments can be evaluated by a variety 
of metrics like throughput, read length, cost per base, and error rate. Most main-
stream NGS systems have short read lengths (35–300 bp), which have a limited 
use for de novo assembly (Treangen & Salzberg 2012), and for the detection of 
structural variations in high resolution. NGS technologies also have a noticeably 
higher error rates in base calls than Sanger sequencing, which affects the 
reliability of detecting genomic variation. Still, it is estimated that long-read 
technologies (e.g. Pacific Biosciences and Oxford Nanopore), producing thou-
sands of bases per read, have even higher sequencing error rates (Besser et al. 
2018; Fox et al. 2014). 
Several large-scale sequencing projects have been finished, but many more 
are ongoing or in the planning stages. The 1000 Genomes Project (1000G) 
(Gibbs et al. 2015) was the first initiative to sequence the genomes of a large 
number of individuals. It was conducted in 2008–2015 and contained data for 
2,504 individuals from 26 populations. Other examples of large-scale publicly 
funded projects are the Cancer Genome Atlas (TCGA) (The Cancer Genome 
Atlas Network 2012) that has generated maps of the key genomic changes in 
many types of cancer, and the related Encyclopedia of DNA Elements (EN-
CODE) project (The ENCODE Project Consortium 2012) to build a 
comprehensive list of functional elements in the human genome. In addition, 
several populations have announced their own sequencing efforts, such as the 
ongoing Genomics England’s ‘100,000 Genomes Project’ (Marx 2015), aiming 
to sequence 100,000 cancer or rare disease patients. Also, there are an 
increasing number of ongoing consortium-based projects. For example, the data 
consortium Genome Aggregation Database (gnomAD) (Lek et al. 2016) has the 
goal of aggregating and harmonizing sequencing data from a wide variety of 
projects. In general, most of the data from large-scale NGS projects has been 
made available for the larger scientific community and it is now implausible to 
15 
conduct any type of genomic analysis without using publicly available data (e.g. 
reference genome, variant frequencies). 
On many occasions, it is necessary to select genomic regions of interest be-
fore sequencing. For instance, one can sequence all protein-coding regions of 
the genome. Compared to WGS, it is more cost-effective, focusing only on the 
~1–2% of the genome that encodes proteins. These approaches are referred as 
‘whole exome sequencing’ (WES) and based on DNA enrichment to target only 
the regions of interest (Mamanova et al. 2010). Several technologies for 
targeted sequence capture have been developed, with the most well-known 
platforms from Illumina, Agilent Technologies, and Roche NimbleGen. 
Turner and colleagues (2009) point out that in the analysis of WES data, at 
least eight relevant performance metrics should be considered: (1) capture 
specificity (the ability to capture only the target regions), (2) uniformity (the 
equal capture over the targets), (3) completeness (the ability to capture all tar-
gets), (4) allelic bias (the equal capture of two alleles of a heterozygous variant), 
(5) multiplexity (the ability to capture all target regions in a single experiment), 
(6) input requirements (the amount and quality of input DNA), (7) scalability 
(the flexibility to handle large sample sizes), and (8) cost (if two methods per-
form equally or sample sizes are large). 
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2. AIMS OF THE STUDY 
The aim of this thesis was to introduce computational and statistical methods 
for the analysis of next-generation DNA sequencing data, and its possible appli-
cations in the Estonian Biobank cohort. 
 
The specific objectives of the thesis were as follows: 
1. To use exome sequencing analysis in gene discovery for Mendelian diseases 
(Refs. I–III). 
2. To illustrate how population-based whole genome sequencing provides 
insight into hematopoietic regulatory mechanisms (Ref. IV). 
3. To quantify how much a population-specific imputation reference panel im-
proves imputation accuracy of low-frequency and rare variants as compared 
to the reference panels based on diverse populations (Ref. V). 
4. To quantify the advantages of genotype imputation with an ethically-
matched reference panel for rare variant association analysis (Ref. VI). 
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3. BIOINFORMATICS AND STATISTICAL METODOLOGY 
3.1. Bioinformatics processing 
To turn sequenced DNA fragments into biologically meaningful information, 
several bioinformatics steps have to be taken. The bioinformatics processing of 
NGS data is quite similar across the different platforms. Any data processing 
from raw sequencing reads to ‘analysis-ready’ genomic variations includes the 
following steps: (1) pre-processing, (2) genotype calling, and (3) post-pro-
cessing (Figure 2). However, each step introduces bias which has to be mea-
sured and taken into account.  
 
 
3.1.1. Base-calling 
Most of the NGS technologies rely on the detection of illumination signals from 
billions of clusters of DNA templates. In other words, base-calling algorithms 
infer the actual nucleotide information from a multitude of high-resolution ima-
ges. The signal intensities are also used for the calculation of per-base quality 
scores. Although base-calling errors may be specific for sequencing platforms, 
they can all be transformed into the standard Phred quality score (Ewing et al. 
1998), given the following formula: 
 
                                      𝑄௉௛௥௘ௗ = −10 logଵ଴ 𝑃 (𝑒𝑟𝑟𝑜𝑟).                                    (1) 
 
For example, an error rate of 1% corresponds to a Phred score of 20. Distribu-
tions of Phred quality scores vary between platforms. For instance, Illumina 
platforms are more error-prone in later cycles, and there are noticeable diffe-
rences between error rates for SNVs and indels across platforms. The ability to 
reduce the error rate of base calls has important consequences for the down-
stream analysis.  
 
3.1.2. Pre-processing 
The method of assembly relying on a reference sequence is called mapping, and 
the method not using reference is referred as de novo assembly. Assembly is a 
complex computational challenge, in which billions of reads have to be placed 
at their correct genomic origin. As all platforms generate reads of much shorter 
lengths than the length of human genome, the target genome is over-sampled 
with short reads from random positions. Because shorter reads have a higher 
probability of being mapped to several identical locations, it increases the 
computational complexity and uncertainty, and makes them not suitable for de 
novo assembly. In addition, alignment algorithms have to take into account 
sequencing errors and deviations from the reference sequence due to SNVs and 
indels. Therefore, alignment is complicated for regions with large differences 
between the reference and the sequenced genome. De novo assembly techni-
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ques, which mostly rely on graph-based representation (Sundquist et al. 2007; 
Zerbino & Birney 2008), may provide potential solutions. Most mapping 
algorithms for short reads (like BWA (Li & Durbin 2009) and Bowtie (Lang-
mead et al. 2009)) make use of Burrows-Wheeler transform (Burrows et al. 
1994) or are hash-based.  
 
 
Figure 2. The GATK best practice framework from raw next-generation sequencing 
data to high-quality genotypes. Pre-processing converts raw-reads into a set of aligned 
reads with associated quality scores (per-base quality scores for each base and mapping 
quality scores for each read). Genotype calling is applied using a Bayesian approach, 
resulting in genotype calls and associated quality scores. Typically, multiple samples 
are called simultaneously. Post-processing separates true variation from artefacts. 
 
 
A best practice guideline of the Genome Analysis Toolkit (GATK) (DePristo et 
al. 2011; Van der Auwera et al. 2013) is nearly ubiquitously used and accepted 
as a gold standard pipeline for the NGS data processing. This guidelines states 
that initial alignments in sequence alignment map (SAM) file have to be sorted 
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and converted to a binary alignment map (BAM) file to make the analysis 
faster. Duplicate reads have to masked, because they are sequenced from the 
same DNA molecule and should not counted in genotype calling. To eliminate 
mapping artefacts, initial alignments are refined by a local realignment to 
identify the most consistent placement of the reads in respect to indels. As 
genotype calling algorithms depend on the base quality scores provided by the 
sequencing machines, these scores need to be recalibrated, because initial 
estimates may be inaccurate. 
 
 
3.1.3. Genotype calling 
Early genotype detection methods counted the number of times each allele is 
observed and applied fixed thresholds, but this leads to a loss of information 
regarding individual read qualities (Nielsen et al. 2011). Most current algo-
rithms utilize a Bayes’ theorem for calculating conditional likelihoods of geno-
types given the read data for a particular individual at a particular site. 
There are several approaches for assigning priors: (1) it can be equal for all 
genotypes, (2) rely on external information (e.g. public databases), or (3) it can 
be improved by jointly analysing multiple individuals. The genotype with the 
highest posterior probability is generally chosen. The genotype likelihood can 
be also calculated using the per-base quality scores. One can take into account 
the pattern of LD at nearby sites, e.g. GATK HaplotypeCaller performs local de 
novo assembly of haplotypes in the region of interest (Van der Auwera et al. 
2013). 
Nowadays, the calling algorithms detect SNVs and small indels simulta-
neously, but the detection of indels is still more problematic due to sequencing 
errors and alignment artefacts. 
 
 
3.1.4. Post-processing 
After calling, each genotype, sample and variant must be evaluated and filtered 
based on quality estimates. The GATK best practice guideline suggests a two-
step variant quality score recalibration (VQSR). In the first step, variant quality 
score is calculated using machine learning methods to assign a well-calibrated 
probability to each variant call in a raw call set. In the second step, calculated 
score can be used for separating true positive and false positive calls. The end 
product of the quality control is a variant call format (VCF) file containing 
high-quality variant calls that can be used in downstream analyses (Van der 
Auwera et al. 2013). 
Finally, variants are usually annotated to assess their molecular and clinical 
significance. A variety of variant annotators are available, the most widely used 
are Variant Effect Predictor (McLaren et al. 2016), Annovar (Wang et al. 2010), 
and snpEFF (Cingolani et al. 2012). Although annotators aggregate plenty of 
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data from different sources, depending on the study design and research ques-
tion, information from additional databases may be required. In general, variant-
level annotation may include the following information: 
1) variant description according to the internationally accepted standard (e.g. 
HGVS nomenclature (Den Dunnen et al. 2016)); 
2) allele frequencies in population databases (e.g. NHLBI Exome Sequencing 
Project (NHLBI-ESP) (Auer et al. 2016), 1000G (Gibbs et al. 2015), and 
ExAC/gnomAD (Lek et al. 2016)) and, if available, in-house databases; 
3)  in silico pathogenicity predictions (e.g. PolyPhen-2 (Adzhubei et al. 2010), 
SIFT (Kumar et al. 2009), and CADD (Kircher et al. 2014)); 
4)  evolutionary conservation scores (e.g. PhyloP (Pollard et al. 2010)); 
5)  additional annotations (e.g. pathogenic variants databases like Human Gene 
Mutation Database (HGMD) (Stenson et al. 2009) or known gene-disease 
databases like Online Mendelian Inheritance in Man (OMIM) (McKusick 
2007)) can be added. 
 
 
3.2. Identification of disease genes by exome sequencing 
WES and WGS allow to explore rare variants explaining the heritability of 
complex traits as well to identify genes underlying rare disorders (known as 
Mendelian diseases). The number of rare Mendelian diseases is estimated to be 
~7000, and for more than two-third of these underlying genes have been dis-
covered (McKusick 2007). For Mendelian diseases, the rapid growth of the 
number of identified causal variants started after the wide deployment of WES 
(Kaiser 2010). Identification of variants that underlie both complex and 
Mendelian traits provides important knowledge about disease mechanisms and 
biological pathways that should lead to improved diagnostics, prevention 
strategies and potential therapeutic targets (Dietz 2010). WES is favourable for 
disease gene discovery, because most variants that are known to underlie rare 
Mendelian diseases are protein-altering (Stenson et al. 2009), and majority of 
rare, protein-coding variants are predicted to be deleterious (Kryukov et al. 
2007). Therefore, the exome represents a highly enriched subset of the genome 
in which to search for variants with large effect sizes (Ng et al. 2010). 
In general, WES strategies depend on the mode of inheritance of a disease, 
the pedigree or population structure, whether a phenotype arises due to de novo 
or inherited variants, and the extent of locus heterogeneity for a disease 
(Bamshad et al. 2011). As tens of thousands of genomic variants can be iden-
tified by WES in each individual, a key challenge is how to efficiently distin-
guish disease-related variants from non-pathogenic variants and sequencing 
artefacts. The most successful strategy of the identification of a novel disease 
gene relies on discrete filtering. First, to prioritize rare or novel candidate 
variants, sequenced data is filtered against population frequency datasets (e.g. 
dbSNP (Sherry et al. 2001), NHLBI-ESP, 1000G, in-house databases) to 
exclude variants that are present at frequencies higher than the expected carrier 
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frequency. It is important to note that described prioritization may discard the 
pathogenic variant, because the underlying assumption that the filtering datasets 
do not contain individuals with the studied disease may be not hold. Or, the 
disease causing variant is present in the population at low frequency in a hetero-
zygous state. This risk is especially relevant for recessive disorders, in which 
variant causes disease if present in a homozygous or compound heterozygous 
state. Next, candidate variants can be prioritized based on their functional class 
(e.g. nonsynonymous, loss-of-function (LoF) variants), by evolutionary con-
servation scores (e.g. PhyloP) and in silico pathogenicity predictions (e.g. 
PolyPhen-2, SIFT, CADD), because pathogenic variants tend to have a marked-
ly higher conservation than benign variants (Cooper et al. 2010). 
Another important factor that can assist unraveling of candidate variants is 
the use of pedigree information. Not necessarily all individuals in a large pedi-
gree have to be sequenced, but the choice depends on the relationships in the 
pedigree and the frequency of a disease causing variant. Sequencing the two or 
three most distantly related individuals with the phenotype of interest can 
restrict the genomic search space most effectively. For the discovery of de novo 
mutations, the most favourable is parent-child trio analysis aiming to filtering 
out all inherited variants. A detailed overview of common WES strategies is 
given by Gilissen et al. (2012). Finally, all detected findings have to be vali-
dated by Sanger sequencing. 
Although, WES has detected thousands of clinically relevant candidate 
variants, there exist constant need for improved sequencing methodology, statis-
tical and bioinformatics methods for better detection, prioritization and interpre-
tation. There are several reasons influencing the success of WES such as se-
quencing not covering target regions entirely, bioinformatics artefacts, the 
disease-causing variant is in the non-coding region, multiple candidate variants 
of unknown significance left after filtering or possible misinterpretation of clini-
cal significance of identified variants. 
 
 
3.3. Genotype imputation 
Genotype imputation is a method for statistically inferring untyped genotypes in 
a set of partially genotyped individuals, lending information from a densely 
genotyped reference panel of phased haplotypes. Haplotype phasing refers to 
the statistical estimation of haplotypes from the genotype data. Imputation 
methods attempt to identify haplotype sharing between individuals in the target 
set and in an imputation reference panel (IRP) (Marchini et al. 2007; Li et al. 
2009). Intuitively, any two individuals can share short stretches of chromosomal 
segments from a distant common ancestor. The true haplotypes underlying the 
observed genotype data are assumed to be imperfect mosaics of the reference 
haplotypes. Points where the reference haplotype changes from one to another 
represent the historical recombination. The observed alleles may differ from the 
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alleles on the underlying reference haplotypes because of mutations, genotype 
errors, or erroneously assigned matches. 
The main advantage of genotype imputation is that it allows to study variants 
that have not been directly genotyped and thereby to increase the resolution of 
genome-wide association studies (GWAS) (Figure 3). Also, imputation is useful 
for combining association results across studies that used different genotyping 
arrays and facilitates fine-mapping to localise association signals by increasing 
genetic variant density in candidate genomic regions (Liu et al. 2010). 
 
 
3.3.1. Genotype imputation methods 
Fundamentally, imputation is very similar to phasing, so most imputation algo-
rithms are based on population genetic models that were originally used in pha-
sing methods. The most important distinction between phasing and imputation 
datasets is that the latter include large proportions of systematically missing 
genotypes (Howie et al. 2009). Most methods for haplotype phase inference can 
also be used to perform imputation, but there are imputation methods that are 
independent of haplotype phase inference (Browning 2008). 
As the number of haplotypes increases, it becomes increasingly difficult to 
efficiently apply the classical recursive computation algorithms. If the number 
of individuals being phased is 𝑁, then the complexity of the algorithm is quad-
ratic. The ability to limit the number of states is essential for datasets with larger 
numbers of individuals (e.g. GWAS-sized datasets). Different imputation 
methods have been developed, summarized in Table 1 by Das et al. (2018), but 
the majority of them based on the statistical model for patterns of LD among 
multiple markers introduced by Li and Stephens (2003). In this framework, a 
subset of haplotypes is selected as a reference set, and each reference haplotype 
represents a hidden state of the hidden Markov models (HMMs) at each marker. 
For instance, this framework is implemented in MaCH (Li et al. 2010), 
IMPUTE (Marchini et al. 2007; Howie et al. 2009), minimac (Howie et al. 
2012; Fuchsberger et al. 2015; Das et al. 2016), and the most recent Beagle 
(Browning & Browning 2016) algorithms. Although all of them employ the 
HMM, they differ from each other in how they define the state space and the 
parameters of the HMM. 
The HMM framework is the most widely used method for inference of 
haplotype phase and missing genotypes. In an HMM, there are a set of observa-
tions that can be used to generate underlying hidden states (Rabiner 1989). In 
case of missing genotype inference, the observed unphased genotypes represent 
the observed data of the HMM, whereas an underlying and unobserved set of 
phased genotypes represent the hidden states. A Markov model is applied to the 
hidden states along the chromosome. 
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Figure 3. An overview of genotype imputation. Genotype imputation uses a densely 
genotyped reference panel of phased haplotypes to infer untyped genotypes in partially 
genotyped individuals. (A) An individual is partially genotyped, with a large number of 
missing genotypes (question marks). (B) Imputation methods require that haplotypes are 
estimated from typed genotype data. (C) These haplotypes are compared to the densely 
genotyped reference panel of haplotypes. Haplotypes of unrelated individuals over short 
stretches of DNA may be related to each other by being identical by descent, therefore 
their haplotypes can be modeled as a mosaic of haplotypes of other individuals. 
Untyped alleles are inferred based on these matched haplotypes. 
 
 
The Li and Stephens model state space is represented as a two-dimensional grid 
of HMM states (Figure 3C), where rows represent reference haplotypes and co-
lumns reference panel markers. Each allele (on each reference haplotype) repre-
sents an HMM state. Each observed haplotype (Figure 3B) proceeds from left to 
right through the all reference markers (from the first to the last). When the path 
switches between reference haplotypes (rows), a new segment in the mosaic of 
reference haplotypes starts. This is determined by the HMM transition probabi-
lities and closely related to the population recombination rate. The HMM emis-
sion probabilities determine the difference between the observed allele and the 
reference allele. Given an observed haplotype with missing allele, the probabi-
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lity of each possible path through the HMM states can be calculated with the 
HMM forward-backward algorithm (Rabiner 1989). Imputed allele probabilities 
at a marker are obtained from the state probabilities. The probability that the 
target haplotype carries a particular allele (probability of imputed allele) is the 
sum of all the state probabilities corresponding to reference haplotypes that 
carry the allele. 
Specialized algorithms are used to compute HMMs. For example, the Viterbi 
algorithm (Viterbi 1967) to find the most likely sequence of hidden states, and 
the Baum forward–backward algorithm (Baum & Eagon 1967) to compute pos-
terior probabilities of hidden states. Then, one can use the Baum–Welch algo-
rithm (or equivalently the EM (expectation–maximization) algorithm (Dempster 
et al. 1977)) to fit model parameters by maximizing the likelihood. Alterna-
tively, Bayesian models typically use Markov chain Monte Carlo (MCMC) 
sampling, attempting to explore the entire model space. Details of the HMM 
algorithms are given by Rabiner (1989). 
As an example, let us consider the algorithm implemented in IMPUTE 
(Marchini et al. 2007) to impute untyped genotypes. Assume that we have data 
at 𝐿 diallelic autosomal variants with two alleles coded as 0 and 1. Let denote 
𝐻 = {𝐻ଵ, … , 𝐻ே}  a set of 𝑁  known haplotypes at 𝐿  markers, where 𝐻௜ =
{𝐻௜ଵ, … , 𝐻௜௅} and 𝐻௜௝ ∈ {0,1}. Let 𝐺 = {𝐺ଵ, … , 𝐺௄} denote the genotype data on 
the 𝐾  individuals with 𝐺௜ = {𝐺௜ଵ, … , 𝐺௜௅}  and 𝐺௜௞ ∈ {0,1,2, 𝑚𝑖𝑠𝑠𝑖𝑛𝑔}. To 
impute the missing genotypes, partition 𝐺 into two disjoint sets: a set 𝑇 that is 
typed in both the target individuals and the reference panel, and a set 𝑈 that is 
untyped in the target sample but typed in the reference panel, 𝐺 = {𝐺், 𝐺௎}. 
The joint distribution of typed and untyped genotype data is assumed, and that 
each individual’s genotype vector can be considered independently of the 
others. Then                            
P(𝐺௎|𝐺், 𝐻) ∝ P(𝐺௎, 𝐺்|𝐻) = P(𝐺|𝐻) = ෑ P(𝐺௜|𝐻).
௄
௜ୀଵ
               (2) 
 
Missing genotypes are inferred through each individual’s genotype vector 𝐺௜, 
conditional on H and a set of parameters. Corresponding HMM can be written 
as 
 
 P(𝐺௜|𝐻, 𝜃, 𝜌) = ෍ P ቀ𝐺௜ቚ𝑍௜(ଵ),  𝑍௜(ଶ), 𝜃ቁ  P ቀ𝑍௜(ଵ),  𝑍௜(ଶ)ቚ𝐻, 𝜌ቁ,        (3)
௓೔
(భ), ௓೔
(మ)
 
 
where 𝑍௜(ଵ) = ቄ𝑍௜ଵ(ଵ), … , 𝑍௜௅(ଵ)ቅ  and 𝑍௜(ଶ) = ቄ𝑍௜ଵ(ଶ), … , 𝑍௜௅(ଶ)ቅ  are two sequences of 
hidden states at the 𝐿 sites with  𝑍௜௟(௝) ∈ {1, … , 𝑁}. These hidden states can be 
thought of as the pair of haplotypes in the set 𝐻 that are being copied to form 
the genotype vector 𝐺௜ . The term P ቀ𝑍௜(ଵ), 𝑍௜(ଶ)ቚ𝐻, 𝜌ቁ models how the pair of 
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copied haplotypes changes along the sequence and is defined by a Markov 
chain in which switching between states depends on an estimate of the fine-
scale recombination map (𝜌) across the genome. The initial state of the Markov 
chain is assumed to follow the Uniform distribution: 
 
 
P ቀ𝑍௜ଵ(ଵ),  𝑍௜ଵ(ଶ)ቚ𝐻, 𝜌ቁ =
1
𝑁ଶ .                                             (4) 
 
 
The term P ቀ𝐺௜ቚ𝑍௜(ଵ),  𝑍௜(ଶ), 𝜃ቁ allows each observed genotype vector to differ 
through mutation from the genotypes determined by the pair of copied haplo-
types and is controlled with the mutation parameter 𝜃. The model allows for 
recurrent mutation at each site, but assumes a uniform mutation rate across the 
genome, 𝜃 = ቀ∑ ଵ௜ேିଵ௜ୀଵ ቁ
ିଵ. Exact marginal probabilities for the missing geno-
types that are conditional on the observed genotype data in the vector 𝐺௜  are 
obtained using the forward-backward algorithm for HMMs. The transition and 
mutation probabilities with precise forms of the HMM terms are given by 
Marchini et al. (2007). 
One can separate imputation into two steps: first, estimate the haplotypes for 
each individual (pre-phasing) and then impute missing genotypes into these 
estimated haplotypes (Howie et al. 2012). This approach reduces the complexity 
of the imputation step from quadratic to linear in the number of reference 
haplotypes, because it is much faster to match a phased haplotype to one refe-
rence haplotype than to match two unphased genotypes to a pair of reference 
haplotypes. 
 
 
3.3.2. Imputation reference panels 
As discussed by Das et al. (2018), several factors can affect imputation accu-
racy such as haplotype phasing in reference and study samples, density of geno-
typing array, size of reference panel, similarities of LD patterns and allele 
frequencies between study samples and the reference panel.  
Publicly available imputation reference panels (IRPs) like the International 
HapMap Project (Frazer et al. 2007; International HapMap 3 Consortium 2010), 
1000G (Gibbs et al. 2015) and Haplotype Reference Consortium (HRC) 
(McCarthy et al. 2016) have been commonly used for imputation. The first 
large-scale imputation studies mostly used the HapMap (Phase II) IRP, which 
consists of microarray-based genotypes from 270 individuals at 3.1 million (M) 
variants (Morris et al. 2012; Speliotes et al. 2010). The 1000G project was the 
first large-scale IRP based on WGS, containing eventually 2,504 individuals 
from 26 populations across the world and up to 81.7 M variants (Artigas et al. 
2015; Leeuwen et al. 2016; Gormley et al. 2016). HRC contains 32,488 refe-
rence individuals, mostly with European ancestry and up to 39.2 M variants. 
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Although above-mentioned ethnically heterogeneous IRPs allow robust imputa-
tion of common variants (minor allele frequency (MAF) ≥ 5%) and low-fre-
quency variants (0.5 ≤ MAF < 5%), they have only limited imputation accuracy 
for rare (MAF < 0.5%) variants (Pasaniuc et al. 2012; Zheng et al. 2012). To 
date, the largest publicly accessible IRP is the Trans-Omics for Precision Medi-
cine (TOPMed) WGS program, containing 62,784 individuals from diverse 
populations and about 463 M variants. 
During the last few years, the results indicate that an IRP specific to the 
particular population (referred to as population-specific IRP) can improve the 
imputation of rarer variants due to more similar allele frequencies and greater 
relatedness between the imputed individuals and the IRP. Population-specific 
IRPs further advance the imputation accuracy of common and low-frequency 
variants in the relevant population (Pistis et al. 2015; Gudbjartsson et al. 2015; 
Deelen et al. 2014). They achieve a higher imputation accuracy compared to the 
1000G panel even in the case of smaller panel sizes (Zhou et al. 2017; Lin et al. 
2018). For example, using imputed data of Sardinian WGS-based IRP, Sidore et 
al. (2015) detected several variants associated with circulating lipid levels in 
Sardinians. In the UK10K project, where the British population-specific IRP 
was combined with 1000G reference panel, several novel genetic variants as-
sociated with medically relevant phenotypes were discovered (Walter et al. 
2015; Huang et al. 2015). In addition, several studies have demonstrated the 
benefit of population-specific IRPs to discover rare variants associated with di-
seases (Holm et al. 2011; Jonsson et al. 2013; Helgason et al. 2013; Steinthors-
dottir et al. 2014). 
 
 
3.3.3. Phasing and imputation accuracy measures 
A standard measure to assess phasing accuracy is the switch error rate (SER) 
(Stephens & Donnelly 2003). A switch error occurs when a heterozygous site 
has phase switched in respect to the previous heterozygous site. The SER is the 
proportion of pairs of heterozygous sites where a switch error has occurred out 
of the total number of possible pairs and can only be assessed when the true 
haplotypes are known (e.g. in simulated data, or when nuclear family data is 
available). SER is zero if all the heterozygotes are phased correctly. 
Several measures have been proposed to assess the accuracy of the imputed 
dose of an allele without the knowledge of the true allele dose: 
1) The squared correlation 𝑟ଶ between the imputed and true dose of an allele 
(Das et al. 2018; Howie et al. 2012). Let 𝑋 = 1 if a chromosome carries the 
allele of interest and let 𝑋 = 0 otherwise. Let 𝑍 be the estimated posterior allele 
probability that 𝑋 = 1. The posterior allele probabilities are correctly calibrated 
if 𝐸(𝑋|𝑍) = 𝑍. If the posterior allele probabilities are correctly calibrated, we 
can use the law of total expectation and the fact that 𝑋ଶ = 𝑋 to obtain 
 
𝐸(𝑋ଶ) = 𝐸(𝑋) = 𝐸൫𝐸(𝑋|𝑍)൯ = 𝐸(𝑍)                                (5) 
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Var(𝑋) = 𝐸(𝑋ଶ) − 𝐸(𝑋)ଶ = 𝐸(𝑍) − 𝐸(𝑍)ଶ                           (6) 
 
Cov(𝑋, 𝑍) = 𝐸(𝑋𝑍) − 𝐸(𝑋)𝐸(𝑍) = 𝐸൫𝐸(𝑋𝑍|𝑍)൯ − 𝐸൫𝐸(𝑋|𝑍)൯𝐸(𝑍)      (7) 
               = 𝐸(𝑍ଶ) − 𝐸(𝑍)𝐸(𝑍) = Var(𝑍). 
Thus, 
 
 𝑟ଶ = ൫Cov(𝑋, 𝑍)൯
ଶ
Var(𝑋)Var(𝑍) =
Var(𝑍)
Var(𝑋) =
𝐸(𝑍ଶ) − 𝐸(𝑍)ଶ
𝐸(𝑍) − 𝐸(𝑍)ଶ .                       (8) 
 
 
2) The allelic 𝑅ଶ estimates the correlation between the true allele dose and the 
most probable (i.e. best guess) allele dose (Browning & Browning 2008). When 
the most probable target allele is the same for all samples, allelic 𝑅ଶ cannot be 
computed. 
3) IMPUTE ‘INFO’ measure is not directly correlation based, but is the ratio of 
the observed and complete information (Marchini & Howie 2010). 
All measures are highly correlated and designed so that 0 indicates a comp-
lete uncertainty in the imputed alleles and 1 refers to no uncertainty (Marchini 
& Howie 2010). All of these measures can be interpreted as the approximate 
reduction in sample size when testing imputed alleles instead of the true alleles 
(Pritchard & Przeworski 2001). In general, poorly imputed markers are re-
moved from downstream analysis based on some threshold (e.g. threshold of 
0.3 or larger for meta-analysis and 0.7 or larger in single cohort GWAS) 
(Zeggini et al. 2008). 
When true genotypes are known (e.g. NGS data is available for the imputed 
individuals), one can estimate imputation accuracy using non-reference (NR) 
sensitivity and non-reference discordancy rate (DePristo et al. 2011). Let 𝑋௜ be 
the number of NR alleles for genotype call 𝑖  in call set 𝑋  and 𝑋௡௥ ={𝑖 ∈ 𝑋: 𝑋௜ > 0}. Then 
 
  
NRୱୣ୬ୱ୧୲୧୴୧୲୷(𝐸, 𝐶) =
|𝐸௡௥ ∩ 𝐶௡௥|
|𝐶௡௥|                                        (9) 
 
and 
NRୢ୧ୱୡ୭୰ୢୟ୬ୡ୷ ୰ୟ୲ୣ(𝐸, 𝐶) =
|𝑖 ∈ 𝐸௡௥ ∪ 𝐶௡௥: 𝐸௜ ≠ 𝐶௜|
|𝐸௡௥ ∪ 𝐶௡௥| ,                  (10) 
 
where 𝐸 and 𝐶 represent evaluated and compared to (inferred with an indepen-
dent methodology) call sets, respectively. For multiple samples, (9) and (10) are 
averaged over samples and generally over MAF categories. 
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4. RESULTS AND DISCUSSION 
4.1. Cohort description 
The Estonian Biobank is a population-based biobank of the Estonian Genome 
Center, University of Tartu (EGCUT), containing almost 52,000 individuals of 
the Estonian population (aged ≥18 years), which closely reflects the age, sex 
and geographical distribution of the Estonian adult population (Leitsalu et al. 
2015). All biobank participants have signed a broad informed consent form, 
which allows linking to national registries, electronic health record databases 
and hospital information systems. The majority of biobank participants have 
been analysed using genotyping arrays, and many of the samples have under-
gone extensive genomic characterization such as exome sequencing (~2,700 
individuals) and high-coverage PCR-free genome sequencing (~3,000 indi-
viduals). In the following studies, we have taken advantage of the valuable data 
resource afforded by the Estonian Biobank to conduct several types of analysis. 
 
 
4.2. Exome sequencing analysis (Refs. I–III) 
The first part of the thesis deals with clinical exome sequencing analysis aiming 
to detect rare disease-related variants. The main challenges of the analysis are: 
(1) to convert sequenced reads to the genotype calls, and (2) to identify disease-
related alleles among multiple non-pathogenic alleles and discard sequencing 
and alignment artefacts. The first part was conducted in a similar manner for all 
three studies: the raw sequencing data were aligned against the GRCh37/hg19 
human genome reference using BWA. The GATK best practice guideline was 
applied for further BAM processing, and the GATK VQSR was used for variant 
quality control. All variants were annotated with Variant Effect Predictor, and a 
custom script was used for additional annotations. In particular, we added allele 
frequencies from population databases such as 1000G and NHLBI-ESP, patho-
genic variant database HGMD, and in silico pathogenicity predictions SIFT and 
PolyPhen-2. In addition, allele counts from our increasing in-house database of 
variants detected among all NGS analyses (WGS and WES) performed in the 
Estonian Biobank were included to the annotation. 
For the second step, to find causal disease-related variants, we determined 
the mode of inheritance and the extent of locus heterogeneity. To find rare or 
novel variants in the same gene shared among affected individuals, we used the 
variants databases – presence in the dbSNP or MAF > 1% in the 1000G or 
NHLBI-ESP datasets shortened our candidate variants list. Another exclusion 
criterion was if the variants were present in the in-house set of Estonian NGS 
samples. Finally, we were focusing on nonsynonymous and LoF variants, in 
silico analysis was performed to verify the variant’s pathogenic status, and all 
findings were confirmed by Sanger sequencing. 
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4.2.1. Analysis of non-syndromic tooth agenesis (Ref. I) 
Tooth agenesis, the congenital absence of one or more permanent teeth, is the 
most common abnormality of human dentition with a prevalence 2.2% – 10.1% 
(Polder et al. 2004). Affected family members often demonstrate a significant 
variability with regard to the position, morphology, symmetry, and number of 
teeth involved. Tooth agenesis occurs either in association with genetic syndro-
mes based on the presence of other inherited abnormalities, as a non-syndromic 
familial trait or as a sporadic finding (Gorlin et al. 2001). Familial tooth age-
nesis has been reported to have either an autosomal-dominant, autosomal-reces-
sive, or X-linked mode of inheritance. It is reported that more than 300 genes 
are involved in tooth morphogenesis (Thesleff 2006), indicating that there are 
many genes underlying regulatory mechanisms of tooth agenesis. 
We conducted exome sequencing analysis in an Estonian family with 
variable degrees of tooth agenesis (Figure 1, Ref. I). Particularly, we sequenced 
one unaffected and four affected individuals. After bioinformatics data pro-
cessing and variant prioritization, we detected 235 novel variants that were 
shared by affected female patients. Among these variants, we discovered a 
novel nonsense mutation c.874G>T (p.Glu292X) in the TNF homology domain 
of EDA – a previously known tooth agenesis candidate gene encoding for 
ectodysplasin-A. Sanger sequencing confirmed that all affected female patients 
were heterozygous carriers, while both the unaffected father and a half-brother 
did not carry this mutation (Figure 2A, Ref. I). Parental testing demonstrated 
that this variant arose de novo, and the risk-associated allele was transmitted to 
affected offspring from their mother. The Glu292 position is highly conserved 
in the other known EDA proteins (Figure 2C, Ref. I), suggesting that it has an 
important function in the protein. We confirmed that EDA mutations are in-
volved in the underlying regulatory pathways of the development of teeth, but 
further in-depth molecular studies are required to clarify their role. 
 
 
4.2.2. Analysis of class III malocclusion (Ref. II) 
Class III malocclusion is a heterogeneous dentofacial phenotype that is skele-
tally characterized by the overgrowth of the mandible, the undergrowth of the 
maxilla, or a combination of both with a prevalence of 4–23% (Singh 1999). 
The inheritance pattern of class III malocclusion is controversial, and it is pre-
sumed to occur as a multifactorial trait for a majority of affected individuals 
with a variety of phenotypic subtypes. Numerous genome-wide linkage scans 
have identified chromosomal regions that might harbour susceptibility genes for 
class III malocclusion in several populations (Yamaguchi et al. 2005; Frazier-
Bowers et al. 2009; Li et al. 2011; Jang et al. 2010; Cruz et al. 2011). 
We performed exome sequencing in four affected and one unaffected sib-
lings from an Estonian family consisting of 21 members from four generations 
(Figure 1, Ref. II). Following bioinformatics data processing and variant 
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filtering detected 14 rare non-synonymous SNVs shared among the four 
affected male siblings and a carrier female (Table 2, Ref. II), including a 
heterozygous missense mutation c.545C>T (p.Ser182Phe) in exon 2 of the 
DUSP6 gene (encoding the dual-specificity phosphatase 6) shared by all five 
siblings. This missense mutation affects a highly conserved amino acid, and in 
silico analysis predicted this variant to be probably pathogenic. None of the 
remaining rare or novel variants were considered plausible candidates. Sanger 
sequencing was used for confirmation of the findings (Figure 2A, Ref. II). The 
Ser182 position is highly conserved in DUSP6 proteins of other species (Figure 
2B, Ref. II), suggesting that this residue is important for the function of the 
DUSP6 protein.  
This study demonstrates that class III malocclusion familial distribution may 
be explained by the presence of a dominant major gene under the influence of 
other modifier genes and environmental factors. The increased knowledge of 
genetic risk factors for class III malocclusion will be necessary for an under-
standing of how the molecular mechanisms underlying this phenotype may 
influence the response to dentofacial and orthodontic treatment and allows clini-
cians to develop more effective targeted intervention strategies to prevent the 
development of class III malocclusion. 
 
 
4.2.3. Analysis of epileptic encephalopathy with  
neonatal beginning (Ref. III) 
Epileptic encephalopathies refer to a severe condition where epileptic activity 
itself can contribute to progressive cognitive, behavioral, and motor dysfunc-
tion. However, the encephalopathic effect of seizures can occur in association 
with any form of epilepsy (Berg et al. 2010). Children with severe early-onset 
epilepsies are thought to be at more risk and typically have a poor prognosis 
(Cross & Guerrini 2013). Several genes have been associated with early infan-
tile epileptic encephalopathy, but determining the underlying cause can be chal-
lenging because of genetic and phenotypic heterogeneity.  
Exome sequencing was performed in affected boy and his healthy parents. 
After bioinformatics data processing and variant prioritization, we identified a 
novel heterozygous missense mutation c.3979A>G in exon 22 of SCN8A, 
predicting a p.Ile1327Val substitution. In silico analysis suggested that the 
mutation has a deleterious effect on the protein function. Also, the affected 
amino acid is located at an extremely conserved position (Figures 2A and 2B, 
Ref. III). The variant c.3979A>G was confirmed as arising de novo in the pro-
band with Sanger sequencing (Figure 2C, Ref. III).  
This study implicated SCN8A in the pathogenesis of epileptic encephalo-
pathy with neonatal beginning and demonstrates the value of WES data in 
clinical settings. Further investigations will be worthwhile to determine the pre-
valence and significance of SCN8A mutations in epileptic encephalopathies. 
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4.3. Population-based genome sequencing analysis with 
blood cell measurements (Ref. IV) 
Hematopoiesis is a process by which blood cells are formed. Although hemato-
poiesis is perturbed in a variety of human blood disorders and shows consider-
able interindividual variation, the underlying basis of the disease etiology and 
variation remains incompletely understood (Sankaran & Orkin 2013). Several 
studies have shown that genetic variants can influence blood cell measurements, 
and result in rare blood disorders (Van der Harst et al. 2012; Ulirsch et al. 2016; 
Orrù et al. 2013). 
To perform a GWAS analysis with 14 blood cell measurements, we used 
high-coverage WGS data of 2,284 individuals and chip-based SNVs of 14,904 
individuals from the Estonian Biobank (Figure S1, Ref. IV). For a small subset 
of the samples (~2000), blood cell measurements were directly assayed in a 
laboratory, for the rest, the measurements were accessed from their electronic 
medical records (EMRs). In general, the blood cell measurements were strongly 
correlated (Figure S2, Ref. IV), also laboratory-based and EMR-based values 
showed high concordance (Figure S3, Ref. IV). 
The single variant analysis detected 17 genome-wide significant associations 
across the various blood cell measurements (Table 1, Ref. IV). All but one of 
these associations have been previously reported and highlighted important bio-
logical mechanisms. However, we detected a previously undiscovered associa-
tion with basophil counts near CEBPA gene (rs78744187; P = 6.19 × 10−38) 
(Figure 1, Ref. IV). Following fine-mapping in 17 detected regions provided 
insight into the molecular regulatory mechanisms. Gene-based burden testing of 
rare variants (MAF < 5%) did not detect significant associations. 
We demonstrated that high-coverage WGS data can be used to discover 
novel common variants associated with human traits and diseases compared to 
chip-based or imputed data. We also showed that in a population-based biobank 
study, one can link genetic data with EMRs to greatly increase sample sizes. 
Although for rare variant analysis, only WGS-based datasets may be likely un-
powered. 
 
 
4.4. Genotype imputation using population-specific 
reference panel (Refs. V-VI) 
A GWAS is a widely-used instrument for detecting associations between gene-
tic variants and phenotypic traits, which mostly captures small to modest effect 
sizes. However, even in aggregate, these explain only a small fraction of the 
heritability of studied traits. Although GWASs have successfully identified 
thousands of common (MAF > 5%) trait-related variants, they are unpowered to 
detect associations with rare variants. To increase the resolution of GWASs, 
genotype imputation is routinely implemented to incorporate variants that are 
not directly genotyped. 
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Although several factors influence imputation accuracy, the genetic simila-
rity between individuals in the imputation reference panel and in the genotyped 
individuals seems to be very dominant, especially for the imputation of rare 
variants (MAF < 1%). In the last part of the thesis, we introduce a WGS-based 
population-specific imputation reference panel and apply it in Estonians. We 
systematically study its impact on imputation accuracy of rare variants (Ref. V) 
and downstream effects of genome-wide association analysis (Ref. VI). 
 
 
4.4.1. Evaluation of imputation accuracy of rare variants using 
population-specific imputation reference panel (Ref. V) 
Imputation accuracy in a specific population depends largely on the size of IRP, 
and genetic similarities between IRP and study samples. However, can smaller 
population-specific IRPs outperform a large number of reference haplotypes 
from diverse populations? 
To address this question, we used high-coverage WGS data of 2,244 indivi-
duals from the EGCUT, and created an imputation reference panel specific to 
Estonians. For comparison, we used two ethnically heterogeneous IRPs (1000G 
and HRC), and two combinations of these panels (EGCUT + 1000G and 1000G 
+ EGCUT) to impute SNVs into 6,394 Estonians (Table 2, Ref. V). IRPs and 
chip-based genotype data was pre-phased using SHAPEIT2 (Delaneau et al. 
2013), followed by IMPUTE2 (Howie et al. 2009) imputation. IMPUTE2 
allows improving imputation accuracy by using two reference panels simulta-
neously by pooling haplotype information across both IRPs. 
We compared phasing speed and accuracy with three programs – SHAPEIT2, 
SHAPEIT2-RA (for read-aware) and Eagle2 (Loh et al. 2016). We observed 
that switch error rate was slightly smaller using SHAPEIT2 or SHAPEIT2-RA, 
but it was achieved by more time-consuming computation compared to Eagle2 
(Table 1, Ref. V). SHAPEIT2-RA did not outperform SHAPIT2 in phasing 
accuracy. 
For each IRP, we studied the number of SNVs as a function of the impu-
tation confidence estimate (INFO-value) and performed separate analysis for 
‘well-imputed’ (INFO > 0.4) and ‘confidently imputed’ (INFO > 0.8) SNVs. 
Although the number of total variants and well-imputed variants obtained with 
the larger diverse panels (1000G and HCR) exceeded the corresponding num-
bers for the population-specific panel, the situation was reversed for confidently 
imputed SNVs (Figure 1b, Ref. V). Looking the same by MAF categories of the 
imputed SNVs (Figure 2, Ref. V), the number of imputed common (MAF  
≥ 5%) variants was very similar across IRPs, but we detected large differences 
for rare variants (MAF < 0.5%), where 3.48 M, 2.54 M and 1.86 M SNVs were 
imputed confidently with EGCUT, HRC and 1000G panels, respectively. 
Population-specific panel outperformed similarly in the analysis of confidently 
imputed LoF and missense variants, providing almost twice as many rare LoF 
variants compared to both diverse panels (Figure 3, Ref. V). 
33 
For further validation, we had exome sequencing data available for 505 im-
puted EGCUT individuals. Treating these WES-based genotype calls as ‘gold 
standard’, we calculated sensitivity and discordancy rates for each imputed 
datasets. For well-imputed common SNVs, all of the IRPs gave similarly high 
sensitivities (88.5–92.4%) (Figure 4a, Ref. V) and low discordancy rates (1.9–
3.4%) (Figure 4b, Ref. V). For low-frequency (0.5 ≤ MAF < 5%) and rare 
SNVs, the three panels that included data from the population-specific panel 
(EGCUT, EGCUT+1000G, and 1000G+EGCUT) yielded a higher sensitivity 
and lower discordancy rate compared to more diverse panels (Table 3, Ref. V). 
The differences were greater for rare SNVs than for low-frequency variants. 
Notably, one-quarter (24.7%) of rare SNVs imputed from the 1000G IRP had 
incorrect genotype calls, whereas the proportion was substantially lower with 
the EGCUT IRP alone (14.1%). We observed similar results for confidently 
imputed variants (Figure S4 and Table S4, Ref. V). In the analysis of finer MAF 
categories, the accuracy of genotype imputation of well-imputed variants de-
creased in the lower MAF bins for all compared IRPs (Figures S5–S9, Ref. V). 
But in case of a population-specific IRP (Figure S7, Ref. V), imputation accu-
racy was significantly better for rare variants, achieving relatively confident im-
putation of variants down to MAF of 0.2%. 
We did not detect any major differences when imputing common variants. 
But imputation of rare variants in Estonians reveals that a population-specific 
IRP (or used in combination with publicly available references such as the 
1000G IRP) outperforms larger IRPs from diverse populations. The majority of 
rare variants imputed with 1000G or HRC IRPs have low confidence. It is im-
portant to note that high imputation confidence estimates (like INFO-value) do 
not guarantee that the corresponding genotypes are inferred correctly. For 
example, diverse IRPs contain divergent haplotypes, which are not present in 
the target samples and may result in SNVs that are not actually polymorphic in 
the study population. Also, we saw that publically available IRPs are limited in 
imputing population-specific SNVs.  
 
 
4.4.2. Advantages of genotype imputation with ethnically-
matched reference panel for rare variant association analyses 
(Ref. VI) 
Population-specific IRPs are implemented in several populations (e.g. in Finns, 
British, Dutch, Sardinians and Icelandic populations), but their genome-wide 
downstream consequences are not comprehensively explored. We determined 
and quantified these differences by performing several comparative evaluations 
of the biologically motivated analysis scenarios. 
We developed a WGS-based IRP containing ethnically closely related 2,279 
Estonians and 1,856 Finns, which is referred to as the Estonian-Finnish (EstFin) 
ethnically matched IRP. We imputed 36,716 unrelated Estonian Biobank samp-
les with the EstFin, and ethnically mixed 1000G IRPs (Figure S1 and Table S1, 
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Ref. VI) and conducted comparative GWAS and gene-wise association testing 
of rare variants (MAF < 1%) with body mass index and seven complex traits 
(Table S2, Ref. VI). Only confidently imputed (INFO > 0.8) variants (SNVs 
and indels) were considered and all association analysis performed separately in 
both imputed datasets (Figure 1, Ref. VI). 
We demonstrated empirically that imputed data based on ethnically-matched 
panel is very promising for rare variant analysis – it captures more population-
specific variants and makes it possible to efficiently identify novel findings 
compared to ethnically-mixed panels. 
  
Genome-wide association analysis, followed by fine-mapping and MAF-
enriched analysis, did not detect any major differences between the imputed 
datasets. Single variant analysis replicated previously reported common variant 
associations – 12 and 13 significant loci based on EstFin and 1000G IRPs, 
respectively (Figure S3 and Table 1, Ref. VI). In the gene-based analysis of rare 
(MAF < 1%) coding (LoF and missense) variants, we observed 10-fold diffe-
rences in the number of tested genes and significant gene-trait associations 
between reference panels. In the EstFin-based imputed data we detected 48 
gene-trait associations and only four in the 1000G-based data (Figures 3 and S4, 
Table 2, Ref. VI). 
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CONCLUSIONS 
Next-generation sequencing technology enables large-scale, routine sequencing 
in large cohorts. In the current thesis, we demonstrated that the analysis of NGS 
data has a huge potential in several fields, but also requires a massive computa-
tional power. Also, with the increase of data volumes, there is an incessant need 
for the development of computational and statistical methods. 
Exome sequencing has been implemented successfully in clinical practice. 
Covering the whole spectrum of protein-coding regions in a cost-effective way, 
it opens new opportunities for quick and exact large-scale screenings not attain-
able with alternative methods like Sanger sequencing or the use of imputed 
datasets. Particularly, exome sequencing is efficient for detecting very rare and 
de novo mutations. The first part of the thesis demonstrated that this approach is 
suitable for the Estonian clinical data as well. We analysed three families with 
Mendelian diseases and detected potentially causative gene variants for each 
case. These projects highlighted that a tight collaboration between data scien-
tists and medical geneticists can lead to findings with considerable impact in the 
research of rare genetic disorders and have the potential to lead to successful 
therapies in the future. 
Also, we experienced that rich genomic data is not always sufficient for a 
successful study. Population-based biobanks (like Estonian Biobank) provide 
numerous opportunities for expanding phenotypic datasets by additional mea-
surements or taking advantages from national databases. We used additional 
blood cell measurements from the electronic medical records and our genome-
wide scan detected previously undiscovered association with basophil counts 
near CEBPA gene, and highlighted their role in the autoimmune regulation. This 
example opens new dimensions for scanning underlying genetic basis for a 
variety of traits and diseases.  
To increase the resolution of genome-wide association analysis, genotype 
imputation is routinely implemented to incorporate variants that are not directly 
genotyped. Imputation is performed based on reference haplotypes. We had an 
opportunity to construct an imputation reference panel to Estonians based on 
high-coverage genome sequencing data. We showed that the utilization of a 
population-specific reference panel provided significantly higher imputation 
confidence for rare variants compared to larger, multi-ethnic panels. Also, the 
population-specific panel yielded a higher sensitivity and lower discordancy 
rate than the more diverse panels. In the downstream association analysis, we 
did not experience differences in respect to the common genetic variants, but 
observed a huge gain in gene-based rare variant analysis. As one of the main 
results of this thesis, the Estonian-specific imputation reference panel is created, 
tested and ready to serve for a long time. This includes genotyping and im-
puting the data in the framework of ongoing personalised medicine initiative to 
invite 100,000 Estonians to join the Estonian Biobank cohort, with the purpose 
to develop more precise and improved disease prevention and treatment guides. 
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SUMMARY IN ESTONIAN 
Arvutuslikud ja statistilised meetodid DNA 
sekveneerimisandmete analüüsimiseks ja rakendused  
TÜ Eesti Geenivaramu andmetel 
Sekveneerimismeetodite areng viimastel aastakümnetel on olnud tormiline. Selle 
tulemusena määrati inimese genoomi DNA järjestus käesoleva sajandi alguses. 
Tänapäeval võimaldavad nn. teise põlvkonna sekveneerimisel (next-generation 
sequencing, NGS) põhinevad meetodid kulu-efektiivselt määrata inimese ge-
noomi järjestuse vähem kui ööpäevaga. Seejuures toodetakse väga suuri andme-
mahtusid, mis omakorda tekitavad mitmeid väljakutseid nii informaatika kui 
statistika valdkonnas. Näiteks on tekkinud vajadus suurte arvutusklastrite järele, 
samuti peab järjepidevalt arendama andmetele sobilikke meetodeid, statistilisi 
mudeleid ja analüüsitarkvara. 
Enne igat analüüsi vajavad sekveneerimisandmed põhjalikku eel-protsessi-
mist ja kvaliteedikontrolli, kus võetakse arvesse võimalikke vigu. Kui andmed 
on analüüsimiseks valmis, on nende kasutusala väga lai, kuna nende abil on või-
malik mõõta väga täpselt geneetilist variatsiooni kogu genoomis võrreldes vara-
semate meetoditega.  
Paljud riigid on alustanud suuremahulisi geeniuuringuid, kaasaarvatud Eesti. 
TÜ Eesti Geenivaramu on juba aastatel 2002–2011 kogunud enam kui 50 000 
inimese geeniproovi ja käesoleval aastal lisandub sellele veel 100 000. Praegu-
seks hetkeks on üle 5 500 geenidoonori DNA-d analüüsitud erinevate NGS 
meetoditega ja just neile andmetele keskendubki käesolev doktoritöö. Välja on 
pakutud üldine raamistik NGS andmete töötluseks ning lisaks on uuritud, kuidas 
võimalikult hästi arvestada Eesti päritolu isikute võimalikku geneetilist eripära. 
Üheks levinud NGS meetodiks on eksoomi ehk kõigi valku kodeerivate 
geenipiirkondade sekveneerimine. See meetod on laialdaselt rakendust leidnud 
meditsiinigeneetikas ühe geeni poolt määratud ehk mendeliaarsete haiguste 
geenimutatsioonide tuvastamisel, kuna võimaldab efektiivselt leida harvu ja de 
novo geenivariante. Doktoritöö esimene osa demonstreerib, et selline lähene-
mine töötas ka Eesti andmetel, kus me analüüsisime kolme perekonna andmeid. 
Kõigil kolmel juhul tegime eksoomi sekveneerimisega kindlaks patogeense 
mutatsiooni, mis lubab tulevikus välja töötada paremaid ravimeetodeid. Siin-
kohal peab lisama, et niisugused projektid eeldavad head koostööd statistikute 
ja meditsiinigeneetikute vahel.  
Samuti viisime läbi kogu genoomi sekveneerimisandmete analüüsi kliinilise 
vere näitajatega. See analüüs tõi välja populatsioonipõhise biopanga eelised, 
mis lisaks rikkalikele genoomiandmetele sisaldab ka väärtuslikku informatsioo-
ni erinevate haiguste ja tunnuste kohta ning vajadusel võimalust neid täiendada 
linkimisega üleriigilistest andmebaasidest. Selles uuringus me küsisime puudu-
olevaid kliinilise vere andmeid E-tervise andmebaasist. Sel viisil teostatud 
uuring aitas meil tuvastada olulisi seoseid CEBPA geenivariantide ja basofiilide 
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arvu vahel, kusjuures viimasel on roll mitmete autoimmuunhaiguste sümpto-
maatikas. Seega näitasime, et populatsioonipõhise biopanga andmetega on või-
malik ka edaspidi edukalt uurida geenide seoseid huvipakkuvate tunnuste ja 
haigustega. 
Ülegenoomsetes assotsiatsiooniuuringutes analüüsitakse eelkõige genotüübi-
andmeid, mis on saadud nn genotüpiseerimiskiipide abil, mis võimaldavad mää-
rata kuni miljon erinevat geneetilist varianti. Selliste uuringute võimsuse suuren-
damiseks kasutatakse puuduvate geenivariantide ennustamist ehk imputeerimist, 
mis põhineb haplotüüpide referentsandmestikul. Muutmaks just Eesti päritolu 
isikute andmeanalüüsi tõhusamaks, kasutasime TÜ Eesti Geenivaramu genoo-
mide sekveneerimisandmeid eestlaste haplotüüpide referentsandmestiku loo-
miseks. Seejärel imputeerisime puuduvaid geenivariante kolmel viisil – kasu-
tades nii eestlaste-spetsiifilist kui ka kahte multi-etnilist referentspaneeli. 
Võrdlustulemused näitasid, et eestlaste-spetsiifilise referentspaneeli kasutamisel 
õnnestus määrata rohkem parema kvaliteediga geenivariante, ning loodud 
paneeli eelis tuleb eriti esile harvaesinevate variantide puhul. 
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